Clinical Trials Browser

Phase 2 × belzutifan × 90 days × Clear all

NCT04924075 2026-02-24

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07187778 2026-01-05

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT06428396 2025-12-26

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms